To: Stock Watcher who wrote (14200 ) 8/31/1999 1:42:00 PM From: Jeffrey L. Henken Read Replies (1) | Respond to
WASP - OTC BB, 1.09 x 1.18 - Wasatch has two operating clinics in Utah which will be profitable very soon however it's my understanding that additional financing will be necessary to begin to implement their expansion phase. I am hoping that we will see an announcement on the funding shortly. Gary Heesch, the company's current CEO, is a research scientist. The company has conducted 14 years of solid research and has a plan here to really take advantage of the competitive advantages of these products. Please read this e mail from the Meyer Group again from yesterday:NEW STOCK! NO OTHER CLINICAL TRIALS WILL BE NEEDED. The FDA has indicated to the Company that after approvals they intend to ban the prescription sale of one of the leading and most expensive treatments for Acne now on the market due to severe side effects. WASP's second stage funding is imminent from a California investment banking group that will allow them to expand from their present two company-owned clinics to a clinic in every state>. Their 6-year plan calls for the opening of 350 clinics that includes every major City in the U.S. Upon FDA approvals, Loreal wants to private label two of their products, and Carter Wallace wants all of them . The stock sells in the $0.90 range; further news on funding and product approvals should drive the stock higher from these levels. Target price short term $2.00 to $3.00.
